IVD & LDT For Autoimmune Diseases Market by Technology, Application

Description

List of Tables

[199 Pages Report] The IVD & LDT For Autoimmune Diseases Market size was estimated at USD 17.27 billion in 2023 and expected to reach USD 18.30 billion in 2024, at a CAGR 5.22% to reach USD 24.68 billion by 2030.

Global IVD & LDT For Autoimmune Diseases Market

KEY MARKET STATISTICS
Base Year [2023]	USD 17.27 billion
Estimated Year [2024]	USD 18.30 billion
Forecast Year [2030]	USD 24.68 billion
CAGR (%)	5.22%

IVD & LDT For Autoimmune Diseases Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the IVD & LDT For Autoimmune Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the IVD & LDT For Autoimmune Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the IVD & LDT For Autoimmune Diseases Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., bioMerieux, Inc., Corgenix, Inc., Creative Biolabs Inc., Diasorin S.P.A., in.vent Diagnostica GmbH, Johnson & Johnson Services, Inc., Microbix Biosystems Inc., PerkinElmer, Inc., Roche Diagnostics Corporation, SQI Diagnostics Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the IVD & LDT For Autoimmune Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Clinical Chemistry
- Coagulation
- Hematology
- Immunoassays
- Microbiology
- Molecular Diagnostics
Application
- Addison's Disease
- Alopecia Areata
- Ankylosing Spondylitis
- Antiphospholipid Antibody Syndrome
- Crohn's Disease
- Diabetes Type 1
- Multiple Sclerosis
- Narcolepsy
- Psoriasis
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Ulcerative Colitis
- Uveitis
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the IVD & LDT For Autoimmune Diseases Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the IVD & LDT For Autoimmune Diseases Market?

3. What are the technology trends and regulatory frameworks in the IVD & LDT For Autoimmune Diseases Market?

4. What is the market share of the leading vendors in the IVD & LDT For Autoimmune Diseases Market?

5. Which modes and strategic moves are suitable for entering the IVD & LDT For Autoimmune Diseases Market?

Product Code: MRR-ED54C46E881C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. IVD & LDT For Autoimmune Diseases Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidences of autoimmune disorders in economies
  - 5.1.1.2. Increasing awareness regarding diagnostic tests for autoimmune diseases
  - 5.1.1.3. Rising development of healthcare infrastructure and growing healthcare expenditure
- 5.1.2. Restraints
  - 5.1.2.1. Concerns regarding extra-neuropsychiatric health problems
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in the field of IVD
  - 5.1.3.2. Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations of IVDs & LDTs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. IVD & LDT For Autoimmune Diseases Market, by Technology

6.1. Introduction
6.2. Clinical Chemistry
6.3. Coagulation
6.4. Hematology
6.5. Immunoassays
6.6. Microbiology
6.7. Molecular Diagnostics

7. IVD & LDT For Autoimmune Diseases Market, by Application

7.1. Introduction
7.2. Addison's Disease
7.3. Alopecia Areata
7.4. Ankylosing Spondylitis
7.5. Antiphospholipid Antibody Syndrome
7.6. Crohn's Disease
7.7. Diabetes Type 1
7.8. Multiple Sclerosis
7.9. Narcolepsy
7.10. Psoriasis
7.11. Rheumatoid Arthritis
7.12. Systemic Lupus Erythematosus
7.13. Systemic Sclerosis
7.14. Ulcerative Colitis
7.15. Uveitis

8. Americas IVD & LDT For Autoimmune Diseases Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific IVD & LDT For Autoimmune Diseases Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa IVD & LDT For Autoimmune Diseases Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Adaptive Biotechnologies Corporation
- 12.1.2. Agilent Technologies Inc.
- 12.1.3. Bio-Rad Laboratories, Inc.
- 12.1.4. bioMerieux, Inc.
- 12.1.5. Corgenix, Inc.
- 12.1.6. Creative Biolabs Inc.
- 12.1.7. Diasorin S.P.A.
- 12.1.8. in.vent Diagnostica GmbH
- 12.1.9. Johnson & Johnson Services, Inc.
- 12.1.10. Microbix Biosystems Inc.
- 12.1.11. PerkinElmer, Inc.
- 12.1.12. Roche Diagnostics Corporation
- 12.1.13. SQI Diagnostics Inc.
- 12.1.14. Thermo Fisher Scientific Inc.
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing